Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nepafenac 0.3% vs vehicle in diabetic patients undergoing cataract surgery
2013-001874-12Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cataract, type 2 diabetes mellitus (T2DM) and diabetes mellitus type 1 (T1D) comparing Nepafenac 0.3% once daily with Vehicle control (2 arms). Primary endpoint: BCVA improvement ≥ 15 letters maintained through Day 90. Started Jul 2013; status: completed.
02
Drugs
nepafenac
03
Conditions
cataracttype 2 diabetes mellitus (T2DM)diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2013-001874-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001874-12.